RIDDLE&CODE
19.1.2021 08:10:45 CET | Business Wire | Press release
RIDDLE&CODE, an innovative European provider of secure infrastructure and technology, and Securosys, a leader in cybersecurity, encryption and digital identity protection, today announced a strategic partnership. The partnership includes the provision of Securosys HSMs for RIDDLE&CODE's Token Management Platform (TPM).
The Token Management Platform is the next generation of RIDDLE&CODE's banking-grade digital asset management solution. Operating in a secure cloud infrastructure, it delivers scalable and flexible custodial and tokenization services to the financial, energy and metal industries in Europe. Regulatory compliance has been achieved in collaboration with the Swiss financial industry.
Securosys HSMs add banking grade security features and relevant compliance processes to RIDDLE&CODE’s TMP platform.
“Our Token Management Platform is now fully interoperable with Securosys HSMs, delivering an unmatched combination of versatility and security to our customers in the energy, finance, material and mobility sectors. We are delighted to partner with Securosys and appreciate its European industry recognition and expertise. The successful deployment and integration of our software with Securosys hardware in the Swiss financial industry made this partnership a natural choice for us.” Alexander Koppel, CEO of RIDDLE&CODE.
Securosys Primus HSMs are a robust solution for securing crypto assets. Its enterprise-grade security is continuously being enhanced with additional features to protect new blockchain systems entering the market. The main advantage of HSMs is a strong security guarantee through tamper resistance and strict access controls for administrative operations.
"We are pleased to deliver our Primus HSM for Riddle&Code's Token Management Platform," said Robert Rogenmoser, CEO of Securosys. "Securosys' Blockchain HSM not only provides the best protection for private keys, but also delivers integrated multisig authentication and algorithms for distributed ledger technologies."
Riddle&Code
RIDDLE&CODE is the leading European Blockchain interface company that builds hardware and software stacks and brings trusted identity to objects and people in the financial markets, energy distribution, mobility and the Internet of Things.
Securosys SA
Securosys SA, based in Zurich, Switzerland, is a market leader in cyber security, encryption, and in securing digital identities. Founded in 2014, Securosys secures the Swiss financial markets on behalf of the Swiss National Bank and protects transactions worth over 100 billion Euros every day. The company supplies more than half of the Tier 1 banks worldwide with hardware security modules developed and built in Switzerland.
Securosys offers a wide range of security network appliances focused on commercial applications. These include communication encryption and key generation and management. All products are developed and manufactured in Switzerland, free from contaminating influences.
Further information can be obtained directly from Securosys SA by e-mail at info@securosys.ch , by calling +41 44 552 31 00, or from its offices in Zürich, Munich, and Hong Kong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom